VerkaziaTM (cyclosporine 0.1%) for the Treatment of Severe Vernal Keratoconjunctivitis is Now Reimbursed by Non-Insured Health Benefits (NIHB) Program
TORONTO--(BUSINESS WIRE)--VerkaziaTM (cyclosporine 0.1%) for the Treatment of Severe Vernal Keratoconjunctivitis is Now Reimbursed by Non-Insured Health Benefits (NIHB) Program